Download PDF

Other users also viewed these articles

Impact of the presence and type of cardiovascular disease on the risk of mortality in type 2 diabetic patients: The DIABET-IC trial José Antonio Gimeno Orna; Ana Belén Mañas Martínez; Luis Rodríguez Padial; Manuel Anguita Sánchez; Vivencio Barrios; Javier Muñiz García; Antonio Pérez Pérez;
Endocrinol Diabetes Nutr. 2024;71:278-89
Treatment of hypertriglyceridaemia with icosapent ethyl in patients with high/very high cardiovascular risk. Consensus document of the Sociedad Española de Cardiología [Spanish Society of Cardiology] and the Sociedad Española de Diabetes [Spanish Diabetes Society] Juan Pedro-Botet; Vivencio Barrios; Víctor Sánchez-Margalet; Juan Tamargo; Francisco Arrieta; José Mª Gámez; José Antonio Gimeno-Orna; Carlos Escobar; Juan José Gómez-Doblas; Antonio Pérez;
Endocrinol Diabetes Nutr. 2023;70 Supl 1:51-62
Real-world evaluation of the efficacy and safety of switching from weekly dulaglutide to weekly semaglutide: The SEMA-SWITCH study Felipe Pardo Lozano; Arantxa Rubio Marcos; Rosa Casañ Fernández; Amparo Bartual Rodrigo; Sergio Martínez-Hervás; Francisco Javier Ampudia-Blasco;
Endocrinol Diabetes Nutr. 2025;72: